Only logged in customers who have purchased this product may leave a review.
FOXO4-DRI
Research Grade Peptide
- Research Grade
- 99% Purity
- Third-Party Verified
Reference Strength: 10mg
R1999,00
Availability: In stock
SKU: F410
FOXO4-DRI
R1999,00
FOXO4-DRI (Proxofim) is a synthetic senolytic peptide researched for selectively eliminating senescent cells through disruption of the FOXO4–p53 interaction.
Availability: In stock
Included with your purchase
Each qualifying product includes 3ml of 0.9% Benzyl Alcohol Bacteriostatic Water.
Complimentary Purchase Kit
Every qualifying vial includes a complimentary purchase kit at no additional cost.
Research Overview
About FOXO4-DRI
A senolytic research peptide developed to target aged or dysfunctional senescent cells.
How It Works in Research
It disrupts the FOXO4–p53 interaction, allowing apoptosis of senescent cells while healthy cells are largely spared.
Research Applications
Healthy ageing research, longevity studies, cellular senescence investigations, tissue-regeneration research and cellular-health studies.
This is a simplified explanation for educational purposes. For detailed scientific information, see the Product Specifications section below.
Functional Performance Profile
Healthy Ageing Research
Cellular Senescence Research
Cellular Defence Research
Key Benefits
- Senescent-cell clearance research, healthy-ageing investigations, tissue-function studies, inflammation-related ageing research and longevity pathway research.
Product Specifications
- Product Name: FOXO4-DRI
- Alternate Name: Proxofim
- Strength: 10mg
Research Information
- Purity: ≥99%
- Appearance: Lyophilised Powder
- Category: Senolytic Research Peptide
Research Reference Parameters — Laboratory Use Only
- Peptide Type: Senolytic Peptide
- Research Focus: Cellular Senescence & Healthy Ageing
- Primary Pathway: FOXO4–p53 Interaction Disruption
For laboratory research only.
Mechanism of Action
FOXO4-DRI blocks the FOXO4–p53 interaction in senescent cells. This allows p53 to translocate and trigger apoptosis in aged dysfunctional cells.
Key Research Characteristics
D-retro-inverso structure, enhanced stability, senolytic pathway research, cellular-ageing studies and tissue-function investigations.
Potential Benefits in Research
Reduced senescent-cell burden, tissue-regeneration research, inflammation-related ageing studies, cellular-health investigations and longevity research.
Safety Profile
Injection-site irritation, redness, swelling, headache, fatigue and individual variability in response. Human safety data remain limited.
Research Applications
Healthy ageing research, longevity studies, cellular senescence investigations, tissue-regeneration research and inflammation-related ageing research.
Research Note: The information presented here is based on published scientific literature and research protocols. Individual results may vary based on research design, subject characteristics, and methodological approaches. Always conduct appropriate due diligence and follow institutional research guidelines.
REFERENCE RECONSTITUTION INFORMATION
This guide explains how research peptides are commonly reconstituted using bacteriostatic water (BAC water), and shows how dosing volumes correspond to syringe units. Always follow sterile preparation techniques when handling research peptides.
Always follow sterile preparation techniques when handling research peptides.
⚠️ DISCLAIMER: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.
General Preparation
⚠️ Important: Allow product vial and BAC water to reach room temperature before reconstituting to reduce condensation uptake
- Draw BAC water with a sterile syringe.
- Inject slowly down the vial wall.
- Avoid foaming.
- Gently swirl until dissolved.
- Do not shake.
- Label vial and refrigerate.
FOXO4-DRI (10mg) - RECONSTITUTION TABLES
Reference Handling Information
Reference information for laboratory handling of FOXO4-DRI.
- Goal: Selectively clear senescent cells.
- Schedule: 5 days on 2 days off subcutaneous injections.
- Dose Range: 0.25–1mg daily.
- Reconstitution Options: 2ml or 3ml BAC water.
- Cycle Length: 8–16 weeks.
Reference Parameters (Dosing Protocol (2ml Reconstitution))
| Phase | Dose | Units | Volume |
|---|---|---|---|
| Weeks 1–2 | 0.25mg | 5 Units | 0.05ml |
| Weeks 3–4 | 0.5mg | 10 Units | 0.10ml |
| Weeks 5–16 | 1mg | 20 Units | 0.20ml |
For laboratory research only.
Reference Parameters (Dosing Protocol (3ml Reconstitution))
| Phase | Dose | Units | Volume |
|---|---|---|---|
| Weeks 1–2 | 0.25mg | 7.5 Units | 0.075ml |
| Weeks 3–4 | 0.5mg | 15 Units | 0.15ml |
| Weeks 5–16 | 1mg | 30 Units | 0.30ml |
For laboratory research only.
Experimental Study Period
STUDY PERIOD
8–16 weeks
These tables show common research dosages. Always use an insulin syringe marked with units for accurate measurement. Contact our research support team for additional guidance.
Balanced diet, exercise, sleep optimisation, hydration and stress management may complement research protocols. Use sterile syringes, rotate sites, document doses and follow consistent handling procedures.
View Certificate of Analysis
View Certificate of Analysis Each batch of FOXO4-DRI is independently tested by third-party laboratories. Download the Certificate of Analysis to verify purity, identity, and quality.
99.7%
Verified Purity
3rd Party
Lab Tested
Certified
Quality Assured
Related products
Reviews
There are no reviews yet.
Only logged in customers who have purchased this product may leave a review.
PURE PERFORMANCE LABS
Recommended Research Products
Explore related compounds commonly viewed alongside this product.
FOR RESEARCH PURPOSES ONLY
This product is intended for research and laboratory use only. Always consult qualified researchers and follow appropriate safety protocols.
Reviews
There are no reviews yet.